Loading clinical trials...

A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice | Clinical Trials | Clareo Health

COMPLETED

A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

NCT00505388•AstraZeneca

Summary

This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use of Symbicort as maintenance and reliever therapy in clinical therapies

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme
•signed and dated informed consent(ICF)
•for patients under-age, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required

Exclusion Criteria

•Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Locations (695)

Research Site

Aarschot, Belgium

Research Site

Achel, Belgium

Research Site

Alleur, Belgium

Research Site

Alsemberg, Belgium

Research Site

Amay, Belgium

Research Site

Angleur, Belgium

Research Site

Ans, Belgium

Research Site

Antheit (= Wanze), Belgium

Research Site

Antwerp, Belgium

Research Site

Assenede, Belgium

Key Dates

Start Date

July 1, 2007

Primary Completion Date

April 1, 2010

Completion Date

April 1, 2010

Last Updated

January 18, 2020

Enrollment

5,137

ACTUAL participants

Conditions

Bronchial Asthma

Behavioral Changes Among Asthmatic Children in Sohag Universty Hospital

NCT06624735

Bronchial Asthma

View study

ACTIVE_NOT_RECRUITINGPHASE2

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

NCT07054034

Bronchial Asthma

View study

COMPLETEDPHASE3

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

NCT06154304

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 18, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

Inclusion Criteria

Exclusion Criteria

Behavioral Changes Among Asthmatic Children in Sohag Universty Hospital

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

the Effect of Use of Vit d and Probiotic as a Supplementaition in the Treatment of Bronchial Asthma in Patient Aged 6 to 50 Year and Its Effect in Decrasing Excerbation.

Echo and Electrocardiographic Findings in Children With Bronchial Asthma At Sohag University Hospital

Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital